“…Goserelin triptorelin T cells induce TH1 shift [45] Inhibition of the PI3K-AKT-mTOR pathway PI3K inhibitors pan-PI3K inhibitor macrophages proinflammatory cytokines production and motility↓ [46] Tregs proliferation↓ [47] T cells cytokines and granzyme B secretion↓ [48], tumor infiltration↑ [49] NK and B cells tumor infiltration↑ [49] p110α inhibitor CD8+ T cells tumor infiltration↑ [50], cytokines production and cytotoxicity↑ [51], CD4+ T cells cytokines production↑ [51], Treg polarization↓ [51] MDSCs tumor infiltration↓ [52] p110β inhibitor macrophages phagocytosis↓ [53] neutrophils cell adhesion, spreading and ROS formation↓ [54] p110γ inhibitor myeloid cells tumor infiltration↓ [55] macrophages M1 polarization↑ [56] CD8+T cells PD-1 and CTLA-4 expression↑ [57], tumor infiltra-tion↑ [49] CD4+Tcells, B cells tumor infiltration↑ [49] p110δ inhibitor macrophages tumor infiltration↓ [58] MDSCs, Tregs immunosuppressive function↓ [59] T cells effector response of effector/memory T cells↓ [60] B cells proliferation, survival and differentiation↓ [61] AKT inhibitors capivasertib Tregs proliferation↓ [47] MDSCs differentiation and viability↓ [62] macrophages AKT1 ablation →M1 phenotype, AKT2 ablation →M2 phenotype [63] mTOR inhibitors rapamycin, everolimus mononuclear cells polarization towards M1 macrophage macrophages proinflammatory cytokine production and motility↓ tolerance was revealed to be partially abolished by tamoxifen though suppression of FasL expression as well as blockade of cancer-derived CCL-2/CCL-5 [86,87]. Intriguingly, SERDs (either fulvestrant or JD128), despite lacking a direct antitumor effect on ER-negative BC, were found to reduce the counts of MDSCs and Tregs as well as increase the infiltration of DCs and CD8 + and CD4 + T cells in 4T1 tumor-bearing mice.…”